Bills Digest no. 88 2010–11
This Digest was prepared for debate. It reflects the legislation as introduced and does not canvass subsequent amendments. This Digest does not have any official legal status. Other sources should be consulted to determine the subsequent official status of the Bill.
Mary Anne Neilsen
Bills Digest Service
23 March 2011
Therapeutic Goods Legislation Amendment (Copyright) Bill 2011
Date introduced: 24 February 2011
House: House of Representatives
Portfolio: Health and Ageing
Commencement: The day after Royal Assent
Links: The links to the Bill, its Explanatory Memorandum and second reading speech can be found on the Bills home page. When Bills have been passed they can be found at the ComLaw website, which is at http://www.comlaw.gov.au/.
The Therapeutic Goods Legislation Amendment (Copyright) Bill 2011 (the Bill) amends the Copyright Act 1968 in order to ensure that the Product Information document issued for generic versions of prescription medicines can be identical to the approved Product Information document of the original medicine.
When the patent of an innovator drug expires, other manufacturers can make generic versions. A generic drug contains the same active ingredient as another product, but is marketed under a different name. In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) recognises the interchangeability of different brands containing the same active ingredient, providing these brands are proven to be bioequivalent.
Generic medicines have an important place in health care. Consumers see generic medicines as an opportunity to access cheaper medicines, while government sees the opportunity to achieve the same health outcomes for patients at a lower cost. The pricing and purchasing of generic medicines in Australia is a significant policy challenge with prices for generic medicines considered still to be high by international standards. The Further Reforms of the Pharmaceutical Benefits Scheme implemented under the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2010 has attempted to address these issues. Amongst other things, it introduced price reductions so that the first listing of a generic version of a medicine now triggers a 16 per cent reduction in the price the Commonwealth pays for the medicine.
As a condition of registration, certain medicines, mainly those prescribed by a doctor, are required to have a Product Information (PI) document which provides information relating to the safe and effective use of the medicine, including information regarding the medicine's usefulness and limitations. PI documents are agreed with the Therapeutic Goods Administration (TGA) as part of the medicine's approval process before it can be made available in Australia.
As the Explanatory Memorandum notes, the information in these documents assists doctors, pharmacists and other health professionals in prescribing and dispensing medicines and also in their consultations with patients, such as to better educate a patient on the medicine they are being given.
PI is defined in the Therapeutic Goods Act 1989 to mean information relating to ‘the safe and effective use of the goods, including information regarding the usefulness and limitations of the goods’. Details about what should be in the PI document are contained in the Australian regulatory guidelines for prescription medicines. It includes technical information about the medicine such as the characteristics of the active ingredient, its indications and contraindications, a description of clinical trials that support the indications, precautions, possible adverse reactions, dosages and storage, and other information relating to the medicine’s safe and effective use.
In relation to PI for generic medicines, the Explanatory Memorandum notes that it has been a long‑standing practice in the TGA for delegates to approve the text of the PI of generic versions of a prescription medicine that is essentially the same as the approved PI of the ‘original’ medicine. The rationale is that it is important for the safe and effective use of the medicine that doctors, pharmacists and other health professionals receive the same information about a medicine regardless of the brand, thus avoiding any perception that differences in the text of the PIs reflect clinical and/or pharmacological differences.
The Bill has not been referred to committee for inquiry.
Position of major interest groups
Generic Medicines Industry Association (GMiA) is reported as welcoming the Bill saying the changes are necessary to ensure generic medicines can continue to be supplied in Australia’.
Other than GMiA, there is little reported comment on the Bill.
The Explanatory Memorandum states that the Bill has no additional financial costs.
The Bill proposes only one significant amendment—it amends the Copyright Act in order to ensure that the PI document issued for generic versions of prescription medicines can be identical to the approved PI document of the original medicine.
The Government’s rationale for the Bill, stated in both the Explanatory Memorandum and the Minister’s second reading speech, is to prevent companies commencing legal action asserting copyright in the text of an approved PI where it is used in the PI of another version of the same medicine.
The Explanatory Memorandum notes that recently a number of pharmaceutical companies that have prescription medicines on the Australian Register of Therapeutic Goods (‘originator companies’) have taken, or threatened to take, legal action on the basis that they own the copyright in the approved PI for their medicines. In particular, in 2008, the Federal Court granted an interlocutory injunction to a pharmaceutical company sponsor of a registered medicine partly on the basis of an argument that copyright in the approved PI for that medicine would be infringed by a competitor’s use of the approved PI for a generic version of the medicine. The Explanatory Memorandum further notes that the Federal Court hearing in this matter is scheduled for March 2011 and the issue of copyright in the approved PI of a registered medicine will be considered by an Australian court for the first time.
The Government states that such actions involving a claim of copyright in PI could have the effect of delaying the listing of generic medicines under the Pharmaceutical Benefits Scheme thus resulting in subjecting the Commonwealth to additional costs as well as artificially prolonging any market exclusivity that the originator company may have under patent law.
It is of note that the Government’s explanatory materials do not identify the pharmaceutical companies involved in Federal court proceedings. However a report by Pharmain Focus notes that copyright issues affecting PI arose in July 2010 in a case between Apotex (a generic drug company) and Sanofi-Aventis over the drug Leflunomide in which, amongst other things, Apotex was denied permission to reproduce a PI document on the grounds of copyright infringement. The details of this 2010 case would appear to be Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd  FCA 601 (8 June 2010) in which Jagot J denies a request to vary the interlocutory orders granted by Lindgren J on 30 October 2008. This matter would appear to be the one referred to in the Explanatory Memorandum, although it is unclear why the details of this particular case are not provided.
As the history of the Copyright Act shows, introducing exceptions to copyright infringement is not done lightly and usually has to be in accordance with quite onerous treaty obligations. The need to defer to international copyright law may be the reason why the Minister’s second reading speech notes that if implemented, the changes will bring Australian law substantially into line with the ‘same labelling requirements’ for medicines in the United States.
In this context, it is also of note that such an amendment of the Copyright Act is not unique and that a similar exception was introduced in 1994 in respect of chemical product labelling approved under the Agricultural and Veterinary Chemical Code ("AGVET Code").
There is only one major amendment— item 1 which inserts proposed section 44BA in Part III of the Copyright Act.
Copyright is designed to prevent the unauthorised use by others of original works. Copyright in Australia exists in works of specified types, including literary and artistic works, by virtue of the Copyright Act. Copyright gives copyright owners a number of exclusive economic rights, such as the right to: reproduce the work in a material form; publish the work; perform the work in public; communicate the work to the public, and make an adaptation of the work.
There are exceptions to the exclusive rights of copyright owners that enable the exercise of certain rights without constituting a copyright infringement. Some of these are set out in sections 40 to 44F of the Copyright Act and include, for example, exceptions that permit fair dealing for certain specified purposes and reproduction of writing on approved labels for containers for chemical product.
The Bill proposes an additional copyright exception as set out in proposed section 44BA.
Proposed subsection 44BA(1) provides that actions under the Therapeutic Goods Act for the purposes of approving PI for certain medicines or approving variations to the PI will not be an infringement of any copyright subsisting in the PI previously approved by the TGA. The effect is to enable, for instance, an applicant for the registration of a generic version of a registered medicine to lodge similar PI to that previously approved by the TGA without infringing copyright.
In addition proposed subsection 44BA(2) provides that the supplying, reproducing, publishing, communicating or adapting, in Australia, of any PI approved under the Therapeutic Goods Act in relation to particular medicines is not an infringement of copyright, providing that any such act is undertaken for a purpose related to the safe and effective use of the medicine.
Item 2 provides that the new infringement exemption provision will apply to acts done on or after commencement. However these acts may relate to PI approved before as well as after the commencement of these provisions.
Item 3 provides for compensation for acquisition of property. This provision follows a standard format which responds to a constitutional requirement that Commonwealth acquisitions of property be compensated for if they have not been undertaken on just terms. Note that the section is not to be inserted into the Copyright Act itself but will remain an item in the Schedule of the Act resulting from passage of this Bill.
Members, Senators and Parliamentary staff can obtain further information from the Parliamentary Library on (02) 6277 2438.
For copyright reasons some linked items are only available to members of Parliament.
Back to top
© Commonwealth of Australia
This work is copyright. Except to the extent of uses permitted by the Copyright Act 1968, no person may reproduce or transmit any part of this work by any process without the prior written consent of the Parliamentary Librarian. This requiremen© Commonwealth of Australiat does not apply to members of the Parliament of Australia acting in the course of their official duties.
This work has been prepared to support the work of the Australian Parliament using information available at the time of production. The views expressed do not reflect an official position of the Parliamentary Library, nor do they constitute professional legal opinion.
Feedback is welcome and may be provided to: firstname.lastname@example.org. Any concerns or complaints should be directed to the Parliamentary Librarian. Parliamentary Library staff are available to discuss the contents of publications with Senators and Members and their staff. To access this service, clients may contact the author or the Library’s Central Entry Point for referral.